Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Many studies have shown some chronic diseases are one of the key risk factors for accelerating cognitive decline. and multimorbidity are common in the elderly population. The evidence of the impact of multimorbidity on dementia among elderly people in China is scarce in detail. This study was performed to examine the association between the prevalence of suspected dementia and multimorbidity, as well as pattern of multimorbidity among the elderly in Shanghai.
Methods: This was a cross-sectional study, with 5040 elderly individuals from 21 communities enrolled. The prevalence of suspected dementia was assessed using the Mini-Mental State Examination (MMSE). In addition, the diagnosed chronic diseases including hypertension, diabetes, hyperlipidemia and coronary heart disease (CHD) were investigated such that multimorbidity was defined as individuals suffering from two or more chronic diseases at the same time. Binary logistic regression models were utilized to analyze the impact of multimorbidity and its patterns on suspected dementia.
Results: Data of 4945 older adults were analyzed. The overall prevalence of suspected dementia and multimorbidity were 15.73% and 35.98%. The influencing factors of dementia from the perspective of single disease, including diabetes, hyperlipidemia, abnormal control of blood glucose and abnormal control of blood lipid. Multivariate analysis showed multimorbidity (OR=1.491, 95%: 1.260-1.765) was significantly negatively associated with dementia, and the risk of dementia in elderly individuals with 2, 3 or more chronic diseases was 1.283 (95%: 1.058-1.555) and 2.034 (95%: 1.600-2.586) times greater, respectively, than those who with no multimorbidity. Notably, elderly individuals with both diabetes and hyperlipidemia had the highest risk of dementia (OR=3.253, 95%: 1.705-6.207).
Conclusion: Multimorbidity played a negative role in dementia among elderly people, dementia risk increases with the number of comorbidities, and the combination of diabetes and hyperlipidemia accentuates dementia risk at a greater level.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312605 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2025.1596281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anticholinergic burden and polypharmacy in patients referred from primary care to tertiary dementia centers in Brazil.
Dement Neuropsychol
August 2025
Hospital Santa Marcelina, São Paulo SP, Brazil.
Unlabelled: Anticholinergic burden (ACB) and polypharmacy are poorly studied in the context of primary care in Brazil.
Objective: To evaluate the ACB and polypharmacy of individuals with suspected dementia referred from primary care to tertiary dementia outpatient clinics in Brazil.
Methods: We performed a cross-sectional study in two tertiary dementia clinics.
Pareidolic Illusions and Associated Lower Regional Gray Matter Volumes in Community-Dwelling Older Adults Without Dementia: The Arakawa 65+ Study.
Int J Geriatr Psychiatry
September 2025
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Objectives: Pareidolic illusions involve perceiving meaningful objects in ambiguous or visually complex stimuli. Although seen in dementia, their presence and associated neuroanatomical basis in older adults without dementia remain unclear. Investigating these illusions in this population may reveal early neurodegenerative changes preceding overt dementia.
View Article and Find Full Text PDFPeriodontal disease and brain amyloid pathology in mild cognitive impairment.
Neurologia (Engl Ed)
September 2025
Instituto de Investigación Biosanitaria de Granada, Avda. de Madrid, 15, 18012 Granada, Spain; Department of Nuclear Medicine, Hospital Universitario Virgen de las Nieves, Avda. Fuerza Armadas, 2, 18014 Granada, Spain.
Introduction: Increases in brain β-amyloid protein (Aβ) levels have been demonstrated in animal models following oral inoculation of periodontopathogens or their enzyme gingipain. We investigated the association between periodontitis and brain Aβ protein levels in mild cognitive impairment (MCI).
Methods: An observational study was designed.
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.
Sci Rep
September 2025
Department of Orthopaedics, Tonglu branch Hospital, Hangzhou First People's Hospital, No.899 Meilin Road, Tonglu, Hangzhou, 330000, Zhejiang Province, China.
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. This study aimed to characterize the real-world adverse event(AE) profile associated with triptorelin using data from the FDA Adverse Event Reporting System(FAERS). We conducted a retrospective pharmacovigilance study utilizing FAERS reports from the first quarter of 2004 to the third quarter of 2024 (2004Q1-2024Q3).
View Article and Find Full Text PDFReliability of Automated Amyloid PET Quantification: Real-World Validation of Commercial Tools Against Centiloid Project Method.
Tomography
July 2025
Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Despite the growing demand for amyloid PET quantification, practical challenges remain. As automated software platforms are increasingly adopted to address these limitations, we evaluated the reliability of commercial tools for Centiloid quantification against the original Centiloid Project method. This retrospective study included 332 amyloid PET scans (165 [F]Florbetaben; 167 [F]Flutemetamol) performed for suspected mild cognitive impairments or dementia, paired with T1-weighted MRI within one year.
View Article and Find Full Text PDF